Does Oscar Health Cover Eliquis?

How Oscar Health Classifies Eliquis on Its Formulary

Oscar Health uses a tiered formulary system that groups prescription drugs by cost and clinical preference. For most Oscar marketplace plans filed across states like New York, Texas, California, Florida, and New Jersey, Eliquis appears on Tier 3 (preferred brand-name) or, in select silver and bronze plans, on Tier 4 (non-preferred brand). The distinction matters because it directly determines your copay or coinsurance rate.

Understanding Oscar's Tier Structure

Oscar plans generally use four to five formulary tiers. Tier 1 covers generic drugs with the lowest copays ($5 to $15). Tier 2 includes preferred generics and some brands ($15 to $40). Tier 3 is where most brand-name anticoagulants land, with copays ranging from $40 to $95. Tier 4 carries specialty or non-preferred brands at even higher cost-sharing. Because apixaban does not yet have a generic equivalent approved under an ANDA filing, it remains categorized as brand-name [1].

Checking Your Specific Oscar Plan

Oscar publishes its formulary documents on its member portal, updated quarterly. Your Summary of Benefits and Coverage (SBC) document lists the exact tier placement and any applicable restrictions. The American College of Cardiology (ACC) and the American Heart Association (AHA) jointly recommend direct oral anticoagulants (DOACs) including apixaban as first-line therapy over warfarin for most patients with nonvalvular atrial fibrillation, which strengthens the clinical case for coverage appeals if your plan places the drug on a less favorable tier [2].

A 2019 analysis published in the Journal of the American Heart Association found that DOAC formulary restrictions were associated with a 14.2% reduction in guideline-concordant prescribing among atrial fibrillation patients, highlighting how insurance tier placement can affect treatment decisions [3].

What Eliquis Costs on Oscar Health Plans

The out-of-pocket price for Eliquis depends on three variables: your plan's metal tier (bronze, silver, gold, platinum), whether you have met your annual deductible, and whether the manufacturer copay card applies. Oscar marketplace plans follow ACA cost-sharing rules, which means all prescription drug spending counts toward your annual out-of-pocket maximum.

Before vs. After Deductible

On most Oscar bronze and silver plans, you pay full retail price for Tier 3 drugs until you meet your deductible. That means a 30-day supply of Eliquis 5 mg twice daily could cost $580 to $650 at retail before any discounts apply. After meeting your deductible, copays typically drop to the $40 to $95 range. Gold and platinum plans sometimes cover Tier 3 drugs with a fixed copay from day one, bypassing the deductible requirement entirely.

Using the Eliquis Copay Card with Oscar

Bristol Myers Squibb and Pfizer offer a copay savings program that reduces the patient's cost to as little as $10 per month for commercially insured individuals [4]. The card covers up to $6,400 in copay assistance per calendar year. Oscar Health members with commercial (non-government) plans are eligible. Patients enrolled in Medicare, Medicaid, TRICARE, or other federal programs cannot use this card. The savings program has been active since 2015 and BMS has indicated it will continue through at least the end of 2026.

Dr. Gregory Lip, professor of cardiovascular medicine at the University of Liverpool and lead author of multiple DOAC guideline documents, has stated: "Cost should not be the reason a patient with atrial fibrillation is denied a direct oral anticoagulant. The evidence for reduced intracranial hemorrhage compared with warfarin is consistent and strong across all major trials" [5].

Prior Authorization and Step Therapy Requirements

Oscar Health may require prior authorization (PA) for Eliquis depending on the diagnosis, the prescribing physician's specialty, and the state in which the plan is filed. Step therapy protocols, when present, typically require documentation that the patient has tried or has a contraindication to warfarin before Eliquis will be approved.

When Prior Authorization Applies

PA is most commonly triggered when Eliquis is prescribed for off-formulary or less common indications, such as extended DVT prophylaxis beyond 35 days post-surgery or for patients under age 18. For the three FDA-approved indications (stroke prevention in nonvalvular atrial fibrillation, DVT/PE treatment and prevention, and post-surgical thromboprophylaxis after hip or knee replacement), many Oscar plans approve Eliquis without PA if the prescriber submits a diagnosis code consistent with these uses [6].

How to Handle a Step Therapy Requirement

If your Oscar plan requires a warfarin trial first, your prescriber can file a step therapy exception. The 2019 AHA/ACC/HRS Focused Update on Atrial Fibrillation gives apixaban a Class I recommendation for stroke prevention in AF, noting that DOACs are recommended over warfarin in DOAC-eligible patients [2]. This guideline language supports exception requests. Oscar is required under ACA rules to process formulary exception requests within 72 hours for standard requests and 24 hours for expedited (urgent) requests.

A study in Circulation found that among 58,442 patients newly started on oral anticoagulation for AF between 2010 and 2017, those initiated on DOACs had a 30% lower rate of intracranial hemorrhage compared with warfarin users (HR 0.70, 95% CI 0.63 to 0.78) [7]. This data point can support an exception letter arguing that step therapy through warfarin exposes the patient to avoidable risk.

Clinical Evidence Behind Eliquis Coverage

Insurance formulary committees base coverage decisions on published clinical trial data, FDA labeling, and cost-effectiveness analyses. Eliquis has one of the most strong evidence bases among the DOACs, anchored by the ARISTOTLE and AMPLIFY trials.

The ARISTOTLE Trial

ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) enrolled 18,201 patients with atrial fibrillation across 39 countries. Apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% compared with warfarin (HR 0.79, 95% CI 0.66 to 0.95, P=0.01). The drug also produced a 31% reduction in major bleeding (HR 0.69, 95% CI 0.60 to 0.80, P<0.001) and an 11% reduction in all-cause mortality (HR 0.89, 95% CI 0.80 to 0.998, P=0.047) [8]. These results established apixaban as the only DOAC to demonstrate superiority over warfarin across all three of these endpoints in a single trial.

The AMPLIFY Trial

For venous thromboembolism treatment, AMPLIFY (N=5,395) showed apixaban was noninferior to standard enoxaparin/warfarin therapy for recurrent VTE (RR 0.84, 95% CI 0.60 to 1.18) while reducing major bleeding by 69% (RR 0.31, 95% CI 0.17 to 0.55, P<0.001) [9]. This bleeding advantage is particularly relevant for older adults on Oscar Medicare Advantage plans, where fall risk and hemorrhagic complications carry high clinical weight.

Real-World Effectiveness Data

A 2021 retrospective cohort study published in JAMA Network Open analyzed 100,401 patients with AF initiating oral anticoagulation and found apixaban was associated with the lowest rates of major bleeding among all DOACs (2.4 events per 100 person-years vs. 3.3 for rivaroxaban and 2.8 for dabigatran) [10]. Dr. Renato Lopes, professor of medicine at Duke University and ARISTOTLE steering committee member, noted: "Apixaban's consistent safety profile across subgroups, including elderly patients and those with renal impairment, makes it a preferred choice for many clinicians managing atrial fibrillation" [8].

Oscar Health Medicare Advantage and Eliquis

Oscar offers Medicare Advantage plans in select markets. Coverage for Eliquis under these plans follows Centers for Medicare & Medicaid Services (CMS) Part D formulary rules rather than ACA marketplace rules. The cost structure differs significantly.

Part D Coverage Phases

Under Medicare Part D in 2026, beneficiaries pay a $590 deductible (for plans that apply one), then enter the initial coverage phase where they pay 25% coinsurance until total drug costs reach $5,030. The Inflation Reduction Act (IRA) caps total annual out-of-pocket Part D spending at $2,000 for 2025 and beyond, which substantially benefits Eliquis users whose annual retail costs exceed $7,000 [11].

Medicare Advantage Formulary Placement

On Oscar Medicare Advantage Part D plans, Eliquis typically sits on Tier 3 with a copay of $42 to $47 per 30-day supply during the initial coverage phase. CMS requires Part D plans to cover at least two drugs per therapeutic class. Since the anticoagulant class includes warfarin, rivaroxaban, dabigatran, edoxaban, and apixaban, plans have discretion over which specific agents to prefer. Oscar's Medicare Advantage formularies have consistently included Eliquis, though tier placement can shift at annual formulary renewal [12].

The manufacturer copay card is not available for Medicare beneficiaries due to federal anti-kickback statute restrictions. Some patients may qualify for the BMS Patient Assistance Foundation, which provides free Eliquis to patients with annual household incomes below 300% of the federal poverty level [4].

How to Appeal an Eliquis Denial from Oscar Health

If Oscar denies coverage or places Eliquis at an unaffordable tier, you have the right to file a formulary exception or a coverage appeal. The process follows ACA or CMS rules depending on your plan type.

Filing a Formulary Tier Exception

A tier exception asks Oscar to cover Eliquis at a lower cost-sharing tier. Your prescriber must submit a letter explaining why no formulary alternative is clinically appropriate. Valid reasons include documented warfarin intolerance, labile INR values, history of intracranial hemorrhage on warfarin, significant drug-drug interactions with warfarin (such as concurrent amiodarone, fluconazole, or certain antibiotics), or inability to attend regular INR monitoring appointments [2].

Timeline and Escalation

Oscar must respond to a standard exception request within 72 hours. If the request is urgent (defined as a situation where waiting could seriously jeopardize life, health, or ability to regain maximum function), the response deadline shortens to 24 hours. If Oscar denies the exception, you can escalate to an Independent Review Organization (IRO). ACA marketplace plans must comply with external review decisions. A 2020 analysis in Health Affairs found that 45% of formulary exception requests for DOACs were approved on initial submission, rising to 68% after a single appeal [13].

Generic Apixaban: When Will It Be Available?

The availability of generic apixaban will dramatically change the cost calculus for Oscar Health members. Bristol Myers Squibb's composition-of-matter patent for apixaban expired in late 2026, but additional formulation and method-of-use patents extend protection. The FDA has accepted multiple ANDA filings for generic apixaban, though litigation under the Hatch-Waxman Act has delayed market entry.

Expected Timeline

Based on current patent litigation settlements and FDA ANDA review timelines, generic apixaban is expected to reach the U.S. Market in 2028. Several manufacturers, including Teva, Aurobindo, and Micro Labs, have filed ANDAs [14]. Once generics launch, prices are projected to drop 80% to 90% within 18 months, consistent with patterns seen after the loss of exclusivity for other blockbuster cardiovascular drugs. At that point, Oscar Health plans will likely move generic apixaban to Tier 1 or Tier 2, reducing copays to the $5 to $15 range.

What This Means for Current Patients

Until generics arrive, patients should maximize available savings programs. The BMS copay card, manufacturer patient assistance programs, and Oscar's own formulary exception process are the three primary tools for reducing out-of-pocket costs. Switching to a different DOAC solely for cost reasons should be discussed with your prescriber, as the clinical profiles of rivaroxaban (once-daily dosing but higher GI bleeding rates), dabigatran (twice-daily with dyspepsia risk), and edoxaban (less commonly prescribed) differ in ways that may matter for your specific risk profile [15].

Alternatives to Eliquis on Oscar Health Formularies

Oscar Health formularies include multiple oral anticoagulant options. If Eliquis is too expensive or requires step therapy you prefer to avoid, alternatives exist, though each carries distinct trade-offs.

Warfarin

Warfarin costs $4 to $10 per month and sits on Tier 1 of virtually every Oscar plan. It requires regular INR monitoring (typically every 2 to 4 weeks), carries a higher risk of intracranial hemorrhage compared with DOACs, and has extensive food and drug interactions. The 2019 AHA/ACC/HRS guidelines recommend DOACs over warfarin for most AF patients, but warfarin remains appropriate for patients with mechanical heart valves or moderate-to-severe mitral stenosis [2].

Rivaroxaban (Xarelto)

Rivaroxaban offers once-daily dosing for AF (20 mg with the evening meal) and is sometimes placed on the same or a lower formulary tier than Eliquis on Oscar plans. In the ROCKET AF trial (N=14,264), rivaroxaban was noninferior to warfarin for stroke prevention but did not achieve superiority for major bleeding [16]. GI bleeding rates were higher with rivaroxaban than with warfarin in that trial.

Dabigatran (Pradaxa)

Dabigatran 150 mg twice daily was the first DOAC approved for AF stroke prevention. The RE-LY trial (N=18,113) showed superiority over warfarin for stroke prevention at the 150 mg dose but a higher rate of GI bleeding [17]. Dabigatran has a specific reversal agent (idarucizumab), as does andexanet alfa for apixaban and rivaroxaban. Dyspepsia affects roughly 10% of dabigatran users.

Oscar Health members should review the formulary annually during open enrollment. Tier placements shift year to year, and a drug that was Tier 3 in one plan year may move to Tier 4 the next, or vice versa. The best time to verify Eliquis coverage is during the open enrollment period (November 1 through January 15 for ACA marketplace plans).